Recipharm signs partnership agreement on pharmaceutical development with Follicum

Recipharm has today announced that it has signed a partnership agreement with Follicum AB in preparation for a clinical trial of the drug candidate FOL-005.

Recipharm has been engaged to formulate and produce the product that will be used in the clinical trial. The engagement also includes developing and validating the analytical methods required.

“Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a strong track record. We look forward to the finished product, which is expected to be ready at the end of the year, in time for the launch of the clinical study,” says Jan Alenfall, CEO of Follicum.

“We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product,” says Maria Lundberg, General Manager of Recipharm in Solna.

Contact information
Maria Lundberg, General Manager Recipharm Pharmaceutical Development, maria.lundberg@recipharm.com, + 46 8 602 52 73
Jan Alenfall, CEO Follicum AB, +46 19 21 97, info@follicum.com

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: t.jervis@defacto.com or a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees.  Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com                                   

About Follicum AB
Follicum focuses on the development of the pharmaceutical candidate FOL-005 which in preclinical studies has both stimulated and inhibited hair growth effectively even at low doses. The Company’s objective is to generate returns and revenues for other future projects by means of a sale or outlicensing of FOL-005 after a successful phase I/IIa trial.

For more information about Follicum, please visit www.follicum.com 

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links

Quotes

We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product
Maria Lundberg
Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a strong track record. We look forward to the finished product, which is expected to be ready at the end of the year, in time for the launch of the clinical study
Jan Alenfall